Cargando…
Identification of IGF2BP3 as an Adverse Prognostic Biomarker of Gliomas
N6-methyladenosine (m(6)A) RNA modification can alter gene expression and function by regulating RNA splicing, stability, translocation, and translation. It is involved in various types of cancer. However, its role in gliomas is not well known. This study aimed to determine the prognostic value of t...
Autores principales: | Sun, Chao, Zheng, Xin, Sun, Yingxin, Yu, Ju, Sheng, Minfeng, Yan, Suji, Zhu, Qing, Lan, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551830/ https://www.ncbi.nlm.nih.gov/pubmed/34721530 http://dx.doi.org/10.3389/fgene.2021.743738 |
Ejemplares similares
-
N(6)-methyladenosine reader IGF2BP3 as a prognostic Biomarker contribute to malignant progression of glioma
por: Zheng, Xin, et al.
Publicado: (2023) -
Identification of Two m6A Readers YTHDF1 and IGF2BP2 as Immune Biomarkers in Head and Neck Squamous Cell Carcinoma
por: Li, Shaojie, et al.
Publicado: (2022) -
Evaluation of the Association of IGF2BP2 Variants With Type 2 Diabetes in French Caucasians
por: Duesing, Konsta, et al.
Publicado: (2008) -
RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma
por: Liu, JinFeng, et al.
Publicado: (2022) -
Genetic Variant in the IGF2BP2 Gene May Interact With Fetal Malnutrition to Affect Glucose Metabolism
por: van Hoek, Mandy, et al.
Publicado: (2009)